Home › Companies › Arrowhead Pharmaceuticals, Inc. › 2025-2026

Arrowhead Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arrowhead Pharmaceuticals, Inc.’s Form 8-K, filed March 20, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.

10Reported items
375Asset managers
3,824Fund votes
March 19, 2026Meeting date

Results at a glance

Meeting of March 19, 2026: 7 items on Arrowhead Pharmaceuticals, Inc.’s Form 8-K, filed March 20, 2026: 7 without a stated outcome.

Material dissent

Elect Director: Michael Perr 69% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arrowhead Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arrowhead Pharmaceuticals, Inc.

These tallies are Arrowhead Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arrowhead Pharmaceuticals, Inc. — official shareholder meeting results, meeting held March 19, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Christopher Anzalon	100,146,366	1,622,011	77,607	--	17,955,558	98%	Not verified	—
Elect Director: Mauro Ferrar	99,784,848	1,986,678	74,458	--	17,955,558	98%	Not verified	—
Elect Director: Hongbo L	92,692,428	8,971,012	182,544	--	17,955,558	91%	Not verified	—
Elect Director: Adeoye Olukoto	100,808,855	852,631	184,498	--	17,955,558	99.1%	Not verified	—
Elect Director: Michael Perr	70,427,879	31,342,814	75,291	--	17,955,558	69%	Not verified	—
Elect Director: Victoria Vakiene	99,264,191	2,506,051	75,742	--	17,955,558	98%	Not verified	—
Elect Director: William Waddill	91,907,466	9,861,644	256,341	--	17,955,558	90%	Not verified	—

Source: Arrowhead Pharmaceuticals, Inc., Form 8-K, filed with the SEC on March 20, 2026 — read the filing on EDGAR.

How asset managers voted at the Arrowhead Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 375 asset managers that disclosed a Arrowhead Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Arrowhead Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Election of Directors: Adeoye Olukotun

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR

Details: votes by 106 asset managers

The 106 asset managers below reported 50,336,475 for, 10,960 against, 25,221 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 50,336,475AGAINST: 10,960ABSTAIN: 25,221

Largest asset managers voting on “Election of Directors: Adeoye Olukotun” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	14,774,438	0	0	For
Vanguard	14,302,610	3	1	For
Fidelity	6,850,753	0	0	For
State Street	3,210,798	0	0	For
Charles Schwab	1,191,957	0	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	0	For
ALGER FUNDS	732,137	0	0	For
Invesco	710,966	0	0	For
T. Rowe Price	597,841	0	0	For
Bridge Builder Trust	463,618	0	0	For
Jackson National	399,092	0	0	For
ALGER FUNDS II	374,810	0	0	For
TIAA	371,985	0	0	For
MUTUAL FUND SERIES TRUST	370,000	0	0	For
Voya	359,465	0	0	For
Equitable	309,770	0	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	0	For
Columbia Threadneedle	221,653	0	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	0	For
Legg Mason	203,339	0	0	For
Prudential/PGIM	193,603	0	0	For
JPMorgan	172,368	0	0	For
Lincoln Financial	171,648	0	0	For
First Trust	141,976	0	0	For
ALGER PORTFOLIOS	132,661	0	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

2. Elect Director: Christopher Anzalon

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 100,146,366AGAINST: 1,622,011

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Election of Directors: Christopher Anzalone

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher Anzalon”): 100,146,366 for, 1,622,011 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 50,336,391 for, 11,043 against, 25,220 abstained.

FOR

FOR: 50,336,391AGAINST: 11,043ABSTAIN: 25,220

Largest asset managers voting on “Election of Directors: Christopher Anzalone” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,774,438	0	For
Vanguard	14,302,608	5	For
Fidelity	6,850,753	0	For
State Street	3,210,717	81	For
Charles Schwab	1,191,957	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	463,618	0	For
Jackson National	399,092	0	For
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	309,770	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	For
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
JPMorgan	172,368	0	For
Lincoln Financial	171,648	0	For
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

3. Elect Director: Mauro Ferrar

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 99,784,848AGAINST: 1,986,678

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Election of Directors: Mauro Ferrari

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mauro Ferrar”): 99,784,848 for, 1,986,678 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 106 asset managers below reported 50,298,877 for, 48,558 against, 25,220 abstained.

FOR

FOR: 50,298,877AGAINST: 48,558ABSTAIN: 25,220

Largest asset managers voting on “Election of Directors: Mauro Ferrari” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,774,438	0	For
Vanguard	14,302,607	6	For
Fidelity	6,850,753	0	For
State Street	3,210,622	176	For
Charles Schwab	1,191,957	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	463,618	0	For
Jackson National	399,092	0	For
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	309,770	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	For
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
JPMorgan	172,368	0	For
Lincoln Financial	171,648	0	For
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

4. Election of Directors: Michael S. Perry

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

59% of fund votes cast · no official result

FORAGAINST

Details: votes by 106 asset managers

The 106 asset managers below reported 29,457,122 for, 20,890,313 against, 25,220 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,457,122AGAINST: 20,890,313ABSTAIN: 25,220

Largest asset managers voting on “Election of Directors: Michael S. Perry” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	263,853	14,510,585	Against
Vanguard	14,302,575	38	For
Fidelity	2,843,919	4,006,834	Mixed
State Street	3,210,622	176	For
Charles Schwab	0	1,191,957	Against
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	438,138	25,480	Mixed
Jackson National	118,615	280,477	Mixed
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	114,090	195,680	Mixed
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	0	218,394	Against
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
JPMorgan	0	172,368	Against
Lincoln Financial	161,298	10,350	Mixed
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

5. Elect Director: Victoria Vakiene

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 99,264,191AGAINST: 2,506,051

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Election of Directors: Victoria Vakiener

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Victoria Vakiene”): 99,264,191 for, 2,506,051 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 106 asset managers below reported 50,336,470 for, 10,965 against, 25,220 abstained.

FOR

FOR: 50,336,470AGAINST: 10,965ABSTAIN: 25,220

Largest asset managers voting on “Election of Directors: Victoria Vakiener” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,774,438	0	For
Vanguard	14,302,605	8	For
Fidelity	6,850,753	0	For
State Street	3,210,798	0	For
Charles Schwab	1,191,957	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	463,618	0	For
Jackson National	399,092	0	For
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	309,770	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	For
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
JPMorgan	172,368	0	For
Lincoln Financial	171,648	0	For
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

6. Elect Director: William Waddill

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%

FOR: 91,907,466AGAINST: 9,861,644

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Election of Directors: William Waddill

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Waddill”): 91,907,466 for, 9,861,644 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 45,773,446 for, 4,573,989 against, 25,220 abstained.

FOR

FOR: 45,773,446AGAINST: 4,573,989ABSTAIN: 25,220

Largest asset managers voting on “Election of Directors: William Waddill” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,774,438	0	For
Vanguard	14,290,441	12,172	For
Fidelity	2,897,410	3,953,343	Mixed
State Street	3,210,798	0	For
Charles Schwab	1,191,957	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	463,618	0	For
Jackson National	118,615	280,477	Mixed
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	309,770	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	For
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
JPMorgan	0	172,368	Against
Lincoln Financial	161,298	10,350	Mixed
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

7. Election of Directors: Hongbo Lu

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

91% of fund votes cast · no official result

FOR

Details: votes by 102 asset managers

The 102 asset managers below reported 45,640,914 for, 4,379,099 against, 25,220 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 45,640,914AGAINST: 4,379,099ABSTAIN: 25,220

Largest asset managers voting on “Election of Directors: Hongbo Lu” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,774,438	0	For
Vanguard	14,281,142	0	For
Fidelity	2,897,410	3,953,343	Mixed
State Street	3,210,798	0	For
Charles Schwab	1,191,957	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	463,618	0	For
Jackson National	118,615	280,477	Mixed
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	309,770	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	For
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
Lincoln Financial	161,298	0	For
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For
Putnam	126,400	0	For

Showing the 25 largest of 102 asset managers. See all 102 in the interactive database.

8. APPROVAL OF THE ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN.

No official matchCOMPENSATION

99.8% of fund votes cast · no official result

FOR

Details: votes by 107 asset managers

The 107 asset managers below reported 50,117,069 for, 57,988 against, 27,721 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 50,117,069AGAINST: 57,988ABSTAIN: 27,721

Largest asset managers voting on “APPROVAL OF THE ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	14,774,438	0	0	For
Vanguard	14,302,605	7	1	For
Fidelity	6,850,753	0	0	For
State Street	3,210,622	176	0	For
Charles Schwab	1,191,957	0	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	0	For
ALGER FUNDS	732,137	0	0	For
Invesco	710,966	0	0	For
T. Rowe Price	597,841	0	0	For
Bridge Builder Trust	463,618	0	0	For
Jackson National	399,092	0	0	For
ALGER FUNDS II	374,810	0	0	For
TIAA	371,985	0	0	For
MUTUAL FUND SERIES TRUST	370,000	0	0	For
Voya	359,465	0	0	For
Equitable	309,770	0	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	0	For
Columbia Threadneedle	221,653	0	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	0	For
Legg Mason	203,339	0	0	For
Prudential/PGIM	193,603	0	0	For
Lincoln Financial	171,648	0	0	For
First Trust	141,976	0	0	For
ALGER PORTFOLIOS	132,661	0	0	For
Putnam	126,400	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

9. ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

36% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST

Details: votes by 372 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 104 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	263,853	14,510,585	0	Against
Vanguard	5,758,316	8,544,297	1	Mixed
Fidelity	2,840,001	4,010,752	0	Mixed
State Street	3,206,955	3,843	0	For
Charles Schwab	0	1,191,957	0	Against
ALGER INSTITUTIONAL FUNDS	0	804,346	0	Against
ALGER FUNDS	0	732,137	0	Against
Invesco	0	710,966	0	Against
T. Rowe Price	0	597,841	0	Against
Bridge Builder Trust	28,891	434,727	0	Mixed
Jackson National	0	399,092	0	Against
ALGER FUNDS II	0	374,810	0	Against
TIAA	371,985	0	0	For
MUTUAL FUND SERIES TRUST	370,000	0	0	For
Voya	0	359,465	0	Against
Equitable	0	309,770	0	Against
DRIEHAUS MUTUAL FUNDS	0	246,088	0	Against
Columbia Threadneedle	0	221,653	0	Against
QUANTITATIVE MASTER SERIES LLC	0	218,394	0	Against
Legg Mason	0	203,339	0	Against
Prudential/PGIM	0	193,603	0	Against
Lincoln Financial	91,232	80,416	0	Mixed
First Trust	0	141,976	0	Against
ALGER PORTFOLIOS	0	132,661	0	Against
Putnam	0	126,400	0	Against

Fund voting reports, all 104 managers: 13,399,436 for, 36,662,706 against, 25,221 abstained, 224 mixed. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 295 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Avoro Capital Advisors LLC	7,371,301	0	For
Fidelity	0	6,718,013	Against
State Street	5,807,294	49,413	For
BlackRock	472,633	4,499,905	Mixed
GEODE CAPITAL MANAGEMENT, LLC	3,271,084	0	For
FRED ALGER MANAGEMENT, LLC	0	2,564,143	Against
Janus Henderson	0	2,468,624	Against
Siren, L.L.C.	1,615,476	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	1,591,559	0	For
Charles Schwab	0	1,356,007	Against
Invesco	0	1,321,542	Against
PICTET ASSET MANAGEMENT SA	0	1,189,439	Against
DRIEHAUS CAPITAL MANAGEMENT LLC	0	1,170,616	Against
Northern Trust	1,103,292	66,455	Mixed
Vanguard	1,011,100	127,769	Mixed
T. Rowe Price	0	1,000,276	Against
MELLON INVESTMENTS Corp	0	857,633	Against
Fisher Asset Management, LLC	0	811,995	Against
UBS	0	795,961	Against
PRINCIPAL GLOBAL INVESTORS	0	716,457	Against
Vestal Point Capital, LP	0	697,700	Against
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	0	595,400	Against
RTW INVESTMENTS, LP	585,682	0	For
Voya	0	496,959	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	483,147	0	For

Institutional-manager reports, all 295 managers: 26,124,383 for, 34,158,040 against, 26,360 abstained, 763 not voted. Showing the 25 largest; see all in the interactive database.

10. RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER…

No official matchAUDIT-RELATED

99.9% of fund votes cast · no official result

FOR

Details: description as filed, votes by 103 asset managers

Description as filed by funds: RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2026.

The 103 asset managers below reported 50,052,516 for, 1 against, 25,220 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 50,052,516AGAINST: 1ABSTAIN: 25,220

Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SE” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,774,438	0	For
Vanguard	14,302,612	1	For
Fidelity	6,850,753	0	For
State Street	3,210,798	0	For
Charles Schwab	1,191,957	0	For
ALGER INSTITUTIONAL FUNDS	804,346	0	For
ALGER FUNDS	732,137	0	For
Invesco	710,966	0	For
T. Rowe Price	597,841	0	For
Bridge Builder Trust	463,618	0	For
Jackson National	399,092	0	For
ALGER FUNDS II	374,810	0	For
TIAA	371,985	0	For
MUTUAL FUND SERIES TRUST	370,000	0	For
Voya	359,465	0	For
Equitable	309,770	0	For
DRIEHAUS MUTUAL FUNDS	246,088	0	For
Columbia Threadneedle	221,653	0	For
QUANTITATIVE MASTER SERIES LLC	218,394	0	For
Legg Mason	203,339	0	For
Prudential/PGIM	193,603	0	For
Lincoln Financial	171,648	0	For
First Trust	141,976	0	For
ALGER PORTFOLIOS	132,661	0	For
Putnam	126,400	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

Largest Arrowhead Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 137,391,000 shares outstanding at the time of that meeting.

Fund voting reports: top Arrowhead Pharmaceuticals, Inc. shareholders by shares voted on “Election of Directors: Adeoye Olukotun”, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	10.75%
2	Vanguard	10.41%
3	Fidelity	4.99%
4	State Street	2.34%
5	Charles Schwab	0.87%
6	ALGER INSTITUTIONAL FUNDS	0.59%
7	ALGER FUNDS	0.53%
8	Invesco	0.52%
9	T. Rowe Price	0.44%
10	Bridge Builder Trust	0.34%

Institutional-manager reports: top Arrowhead Pharmaceuticals, Inc. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Avoro Capital Advisors LLC	5.37%
2	Fidelity	4.89%
3	State Street	4.26%
4	BlackRock	3.62%
5	GEODE CAPITAL MANAGEMENT, LLC	2.38%
6	FRED ALGER MANAGEMENT, LLC	1.87%
7	Janus Henderson	1.80%
8	Siren, L.L.C.	1.18%
9	DEERFIELD MANAGEMENT COMPANY, L.P.	1.16%
10	Charles Schwab	0.99%

Reported Arrowhead Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Arrowhead Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	13.22%	13F
Vanguard Group	11.13%	13F
Entities affiliated with Avoro Capital Advisors LLC	10.18%	DEF14A
Avoro Capital Advisors LLC	10.06%	13G
FMR (Fidelity)	5.29%	13F
State Street	4.73%	13F
Geode Capital	3.11%	13F
Christopher Anzalone	2.76%	DEF14A
Invesco	2.39%	13F
Goldman Sachs	1.27%	13F

Percentages above are of 137,391,000 shares outstanding, as reported by Arrowhead Pharmaceuticals, Inc. on its Form 10-Q dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arrowhead Pharmaceuticals, Inc.’s 10-Q dated December 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At Arrowhead Pharmaceuticals, Inc.'s shareholder meeting held March 19, 2026, in the 2025-2026 proxy season, 375 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,824 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Arrowhead Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. — the reporting funds and managers cast 36% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Arrowhead Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.